Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 20/20 | 0.66 |
| ▸ | TBXA2R | P21731 | 10/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6191173 | 0.85 | PTGER1 (0.75) | PTGER1TBXA2RCYP2C9CYP3A4 | |
| SCHEMBL5107180 | 0.83 | PTGER1 (0.64) | PTGER1TBXA2RCYP2C9CYP3A4 | |
| SCHEMBL6605099 | 0.81 | PTGER1 (0.81) | PTGER1TBXA2RCYP2C9CYP3A4 | |
| SCHEMBL5100875 | 0.79 | PTGER1 (1.00) | PTGER1TBXA2RCYP2C9CYP3A4 | |
| SCHEMBL7495587 | 0.79 | PTGER1 (0.66) | PTGER1TBXA2RCYP2C9CYP3A4 | |
| SCHEMBL6607313 | 0.78 | PTGER1 (0.74) | PTGER1TBXA2RCYP2C9 | |
| SCHEMBL6193896 | 0.78 | PTGER1 (0.76) | PTGER1TBXA2RCYP2C9CYP3A4 | |
| SCHEMBL6191978 | 0.78 | PTGER1 (0.80) | PTGER1TBXA2RCYP2C9CYP3A4 | |
| SCHEMBL6245317 | 0.77 | PTGER1 (1.00) | PTGER1TBXA2RCYP2C9CYP3A4 | |
| SCHEMBL6604857 | 0.77 | PTGER1 (1.00) | PTGER1TBXA2RCYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040198730-A1 | Pyridylfurans and pyrroles as raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-10-07 | — | — | US | claimed |
| EP-1432699-A1 | PYRIDYLFURANS AND PYRROLES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2004-06-30 | — | — | EP | claimed |
| WO-2003022832-A1 | PYRIDYLFURANS AND PYRROLES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-03-20 | — | — | WO | claimed |
| US-7446106-B2 | Pyridylfurans and pyrroles as Raf kinase inhibitors | SMITHKLINE BEECHAM PLC (GB) | 2008-11-04 | — | — | US | disclosed |
| US-20040198730-A1 | Pyridylfurans and pyrroles as raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-10-07 | — | — | US | disclosed |
| EP-1432699-A1 | PYRIDYLFURANS AND PYRROLES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003022832-A1 | PYRIDYLFURANS AND PYRROLES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198730-A1 | Pyridylfurans and pyrroles as raf kinase inhibitors | BRAF, ARAF, RAF1 | PTGER1 1072/4885TBXA2R 2047/4885CYP2C9 3932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.